|
| Exchange Disseminated Time | With reference to the news item appearing in the financial daily titled "Glenmark to out-license molecule for pain management", Glenmark Pharmaceuticals Ltd has Clarified to BSE as under"
"As a part of its business, the Company enters into discussions with various Pharmaceutical Companies (Interested licensees) with respect to its innovative product pipeline. Such discussions are mostly exploratory and may or may not result in a business deal.
We confirm that at present there are no negotiations taking place.
In the circumstances, we submit that this news item does not require disclosure under Clause 36 of the Listing agreement." |
|
|